Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study.
Effectiveness
observational
palmoplantar psoriasis
psoriasis
real-life
real-world
secukinumab
Journal
Expert opinion on biological therapy
ISSN: 1744-7682
Titre abrégé: Expert Opin Biol Ther
Pays: England
ID NLM: 101125414
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
20
1
2022
medline:
7
4
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Palmoplantar psoriasis is difficult to treat and often recalcitrant to conventional therapies. Clinical trials have demonstrated the efficacy and safety of secukinumab for this debilitating psoriasis form, but real-life evidence is currently limited. Therefore, here we described the outcomes of patients treated with secukinumab in clinical practice. This was a real-life, retrospective, observational study involving patients with palmoplantar psoriasis treated with secukinumab (300 mg, subcutaneously) at seven dermatologic clinics in Italy. Treatment effectiveness was evaluated based on the changes of the Psoriasis Area and Severity Index (PASI) and palmoplantar (pp) PASI during treatment and by recording safety and tolerability issues over 104 weeks. Forty-three patients initiated treatment with secukinumab. Previous treatments included topical and systemic therapies; half of patients had already tried one or more biologics. Secukinumab improved mean PASI rapidly and substantially with a 78.2% decrease at 16 weeks. Mean ppPASI also improved substantially, but more gradually, with reductions of 55.0% and 79.3% at 16 and 104 weeks, respectively. Approximately half of patients achieved complete skin clearance at 40 weeks. Secukinumab was well tolerated and no relevant treatment-related adverse events were reported. Secukinumab appears to be effective for the treatment of palmoplantar psoriasis also in the real-life setting.
Sections du résumé
BACKGROUND
BACKGROUND
Palmoplantar psoriasis is difficult to treat and often recalcitrant to conventional therapies. Clinical trials have demonstrated the efficacy and safety of secukinumab for this debilitating psoriasis form, but real-life evidence is currently limited. Therefore, here we described the outcomes of patients treated with secukinumab in clinical practice.
RESEARCH DESIGN AND METHODS
METHODS
This was a real-life, retrospective, observational study involving patients with palmoplantar psoriasis treated with secukinumab (300 mg, subcutaneously) at seven dermatologic clinics in Italy. Treatment effectiveness was evaluated based on the changes of the Psoriasis Area and Severity Index (PASI) and palmoplantar (pp) PASI during treatment and by recording safety and tolerability issues over 104 weeks.
RESULTS
RESULTS
Forty-three patients initiated treatment with secukinumab. Previous treatments included topical and systemic therapies; half of patients had already tried one or more biologics. Secukinumab improved mean PASI rapidly and substantially with a 78.2% decrease at 16 weeks. Mean ppPASI also improved substantially, but more gradually, with reductions of 55.0% and 79.3% at 16 and 104 weeks, respectively. Approximately half of patients achieved complete skin clearance at 40 weeks. Secukinumab was well tolerated and no relevant treatment-related adverse events were reported.
CONCLUSIONS
CONCLUSIONS
Secukinumab appears to be effective for the treatment of palmoplantar psoriasis also in the real-life setting.
Identifiants
pubmed: 35043741
doi: 10.1080/14712598.2022.2029841
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM